Secretome of Undifferentiated Neural Progenitor Cells Induces Histological and Motor Improvements in a Rat Model of Parkinson's Disease
Open Access
- 20 September 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 7 (11) , 829-838
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder that results from the death of dopamine (DA) neurons. Over recent years, differentiated or undifferentiated neural stem cells (NSCs) transplantation has been widely used as a means of cell replacement therapy. However, compelling evidence has brought attention to the array of bioactive molecules produced by stem cells, defined as secretome. As described in the literature, other cell populations have a high-neurotrophic activity, but little is known about NSCs. Moreover, the exploration of the stem cell secretome is only in its initial stages, particularly as applied to neurodegenerative diseases. Thus, we have characterized the secretome of human neural progenitor cells (hNPCs) through proteomic analysis and investigated its effects in a 6-hydroxidopamine (6-OHDA) rat model of PD in comparison with undifferentiated hNPCs transplantation. Results revealed that the injection of hNPCs secretome potentiated the histological recovery of DA neurons when compared to the untreated group 6-OHDA and those transplanted with cells (hNPCs), thereby supporting the functional motor amelioration of 6-OHDA PD animals. Additionally, hNPCs secretome proteomic characterization has revealed that these cells have the capacity to secrete a wide range of important molecules with neuroregulatory actions, which are most likely support the effects observed. Overall, we have concluded that the use of hNPCs secretome partially modulate DA neurons cell survival and ameliorate PD animals’ motor deficits, disclosing improved results when compared to cell transplantation approaches, indicating that the secretome itself could represent a route for new therapeutic options for PD regenerative medicine.Keywords
Funding Information
- Portuguese Foundation for Science and Technology: Ciência 2007 Program and IF Development (IF/00111/2013)
- Canada Research Chair in Biomedical Engineering
- Northern Portugal Regional Operational Programme
- European Regional Development Fund
- FEDER
- Foundation for Science and Technology
- National Mass Spectrometry Network (REDE/1506/REM/2005)
This publication has 76 references indexed in Scilit:
- Neuroprotective Function of DJ-1 in Parkinson’s DiseaseOxidative Medicine and Cellular Longevity, 2013
- Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficitsMolecular Neurodegeneration, 2013
- New perspectives of tissue remodelling with neural stem and progenitor cell-based therapiesCell and tissue research, 2012
- DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathwayProceedings of the National Academy of Sciences, 2010
- Trophic factors therapy in Parkinson's disease2009
- Oxidative Stress in Parkinson's DiseaseAnnals of the New York Academy of Sciences, 2008
- Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's diseaseExperimental Neurology, 2008
- Increases in expression of 14‐3‐3 eta and 14‐3‐3 zeta transcripts during neuroprotection induced by Δ9‐tetrahydrocannabinol in AF5 cellsJournal of Neuroscience Research, 2007
- DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in MiceMolecular Therapy, 2007
- Semaphorin 7A promotes axon outgrowth through integrins and MAPKsNature, 2003